Common and rare TBK1 variants in early-onset Alzheimer disease in a European cohort.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Verheijen Jan, van der Zee Julie, Gijselinck Ilse, Van den Bossche Tobi, Dillen Lubina, Heeman Bavo, Gómez-Tortosa Estrella, Lladó Albert, Sanchez-Valle Raquel, Graff Caroline, Pastor Pau, Pastor Maria A, Benussi Luisa, Ghidoni Roberta, Binetti Giuliano, Clarimon Jordi, de Mendonça Alexandre, Gelpi Ellen, Tsolaki Magda, Diehl-Schmid Janine, Nacmias Benedetta, Almeida Maria Rosário, Borroni Barbara, Matej Radoslav, Ruiz Agustín, Engelborghs Sebastiaan, Vandenberghe Rik, De Deyn Peter P, Cruts Marc, Van Broeckhoven Christine, Sleegers Kristel, BELNEU Consortium, EU EOD Consortium
Аннотация
TANK-binding kinase 1 (TBK1) loss-of-function (LoF) mutations are known to cause frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS), often combined with memory deficits early in the disease course. We performed targeted resequencing of TBK1 in 1253 early onset Alzheimer's disease (EOAD) patients from 8 European countries to investigate whether pathogenic TBK1 mutations are enriched among patients with clinical diagnosis of EOAD. Variant frequencies were compared against 2117 origin-matched controls. We identified only 1 LoF mutation (p.Thr79del) in a patient clinically diagnosed with Alzheimer's disease and a positive family history of ALS. We did not observe enrichment of rare variants in EOAD patients compared to controls, nor of rare variants affecting NFκB induction. Of 3 common coding variants, rs7486100 showed evidence of association (OR 1.46 [95% CI 1.13-1.9]; p-value 0.01). Homozygous carriers of the risk allele showed reduced expression of TBK1 (p-value 0.03). Our findings are not indicative of a significant role for TBK1 mutations in EOAD. The association between common variants in TBK1, disease risk and reduced TBK1 expression warrants follow-up in FTD/ALS cohorts.